Polycythemia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 23: | Line 23: | ||
*4-year [[Mortality rate|mortality]] rate is >10%. | *4-year [[Mortality rate|mortality]] rate is >10%. | ||
*On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average. | *On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average. | ||
*[[Comorbidities]] such as [[cardiovascular]] diseases, other blood, and [[lymphatic]] disorders, [[vascular]] disorders, mass occupying lesions in the [[thorax]], respiratory system, infections, etc. accounted for more deaths more often. | *[[Comorbidities]] such as [[cardiovascular]] diseases, other blood, and [[lymphatic]] disorders, [[vascular]] disorders, mass occupying lesions in the [[thorax]], respiratory system, infections, etc. accounted for more deaths more often.<ref name="pmid23281576">{{cite journal| author=Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH | display-authors=etal| title=Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. | journal=Eur J Haematol | year= 2013 | volume= 90 | issue= 3 | pages= 228-36 | pmid=23281576 | doi=10.1111/ejh.12064 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23281576 }}</ref> | ||
*[[Thrombosis|Thrombotic]] complications were the most common cause of death followed by [[hematologic]] [[malignancy]]. | *[[Thrombosis|Thrombotic]] complications were the most common cause of death followed by [[hematologic]] [[malignancy]]. | ||
Revision as of 16:26, 2 March 2021
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polycythemia epidemiology and demographics |
|
Risk calculators and risk factors for Polycythemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
- Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies.
Epidemiology and Demographics
Incidence
- The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals in the United States.[1][2]
- Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females.
Prevalence
- The prevalence of polycythemia vera in the 7 MM countries was 283,442 in 2017.
- Prevalence of polycythemia vera was the highest in the US in 2017 at 157,290, out of which 62,916 cases were asymptomatic and 94,374 were symptomatic.
- 22 cases per 100,000 people.
Case-fatality rate/Mortality rate
- 4-year mortality rate is >10%.
- On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average.
- Comorbidities such as cardiovascular diseases, other blood, and lymphatic disorders, vascular disorders, mass occupying lesions in the thorax, respiratory system, infections, etc. accounted for more deaths more often.[3]
- Thrombotic complications were the most common cause of death followed by hematologic malignancy.
Age
- It has been noted that PV is more common in the age group >75.
- Median age of diagnosis is 60.[4]
Race
- Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians.
Gender
- Generally, there is no sex predilection.[5]
- In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females.
Region
References
- ↑ Berglund S, Zettervall O (1992). "Incidence of polycythemia vera in a defined population". Eur J Haematol. 48 (1): 20–6. doi:10.1111/j.1600-0609.1992.tb01788.x. PMID 1730276.
- ↑ Ridell B, Carneskog J, Wedel H, Vilén L, Høgh Dufva I, Mellqvist UH; et al. (2000). "Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992". Eur J Haematol. 65 (4): 267–71. doi:10.1034/j.1600-0609.2000.065004267.x. PMID 11073167.
- ↑ Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH; et al. (2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur J Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
- ↑ "StatPearls". 2021. PMID 32491592 Check
|pmid=value (help). - ↑ "StatPearls". 2021. PMID 32491592 Check
|pmid=value (help). - ↑ "StatPearls". 2021. PMID 32491592 Check
|pmid=value (help). - ↑ Johansson P (April 2006). "Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia". Semin Thromb Hemost. 32 (3): 171–3. doi:10.1055/s-2006-939430. PMID 16673273.